Robert E. George - 07 Jun 2021 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Reporting relationship: Director
Issuer ticker: MBRX
Reported as of: 07 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2021, 16:25:01 UTC
Next SEC filing: 22 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Foster by Power of Attorney

Key filing fact

Robert E. George filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 09 Jun 2021.

Key facts

This page summarizes Robert E. George's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2021, 16:25.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBRX transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +10,000
Change %: +60%
Price
Shares after: 26,668
Date: 07 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $3.95
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Footnote F2

The options were issued in connection with the reporting person's Board of Director service to the Company.